Cosmo Bio Co

Cosmo Bio Co Net Change in Cash

The Net Change in Cash of Cosmo Bio Co (3386.T) as of Oct 26, 2026 is 354.00 M JPY. In the previous year, Net Change in Cash was -433.00 M JPY — a change of -181.76% (higher).

Net Change in Cash

354.00 MJPY

YoY

-181.76%

Last updated:

Net Change in Cash of Cosmo Bio Co is 2025 354.00 M JPY. Net Change in Cash of Cosmo Bio Co was 2024 -433.00 M JPY. It decreases by -181.76% higher compared to the previous year.

The Cosmo Bio Co Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
684.00 M JPY
Jan 1, 2019
348.00 M JPY
Jan 1, 2020
743.00 M JPY
Jan 1, 2021
96.00 M JPY
Jan 1, 2022
-219.00 M JPY
Jan 1, 2023
-210.00 M JPY
Jan 1, 2024
-433.00 M JPY
Jan 1, 2025
354.00 M JPY
The Cosmo Bio Co Net Change in Cash history
YEARNet Change in CashYoY
354.00 MJPY-181.76%
-433.00 MJPY+106.19%
-210.00 MJPY-4.11%
-219.00 MJPY-328.13%
96.00 MJPY-87.08%
743.00 MJPY+113.51%
348.00 MJPY-49.12%
684.00 MJPY-359.09%
-264.00 MJPY-148.09%
549.00 MJPY-292.63%
-285.00 MJPY+448.08%
-52.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmo Bio Co stock

Net Change in Cash of Cosmo Bio Co is 354.00 M JPY in 2025.

Net Change in Cash of Cosmo Bio Co changed from -433.00 M JPY to 354.00 M JPY, representing a -181.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Cosmo Bio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cosmo Bio Co

All Key Metrics — Cosmo Bio Co